Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Kennedy critics have concerns about the work he’s done to sow doubts around vaccine safety and his potential to profit off lawsuits over drugmakers.

Courtney Breen, senior analyst of U.S. biopharmaceuticals at Bernstein, discusses Merck's slump in the market following its ...

Vamil Divan, Guggenheim Securities biopharmaceutical analyst, joins 'Power Lunch' to discuss Merck's troubles in China.